✦ LIBER ✦

PUK9 SEVEN YEAR TRENDS OF PHARMACY BENEFIT ERYTHROPOIESIS-STIMULATING AGENT UTILIZATION AND COST CONSIDERATIONS OF CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS

✍ Scribed by F Vekeman; RA Bailey; F Laliberté; M Senbetta; RS McKenzie; P Lefebvre

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PUK27 ERYTHROPOIESIS-STIMULATING AGENT D

✍ MH Lafeuille; RA Bailey; F Laliberté; M Senbetta; F Vekeman; RS McKenzie; K Dea; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

PUK8 ERYTHROPOIESIS-STIMULATING AGENTS U

✍ MH Lafeuille; RA Bailey; F Laliberté; M Senbetta; A Blacksmith; P Lefebvre 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB

147: Drug Utilization and Cost Considera

✍ Samir Mody; Francis Vekeman; Antoine Gosselin; Brahim Bookhart; R. Scott McKenzi 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 191 KB

130: Drug Utilization and Cost Considera

✍ François Laliberté; Patrick Lefebvre; Francis Vekeman; Janice Lopez; R. Scott Mc 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 186 KB

PUK28 ASSESSMENT OF RECENT ERYTHROPOIESI

✍ MH Lafeuille; RA Bailey; F Laliberté; M Senbetta; F Vekeman; RS McKenzie; A Blac 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB